All articles tagged with #johnson and johnson
Johnson & Johnson has agreed to pay $5.5 billion to settle about 69,000 US talc-related lawsuits alleging its talc-based baby powder caused ovarian cancer; the settlement requires 95% claimant acceptance and does not cover UK claims, where a separate large case is underway, while J&J maintains there’s no proven link between talc and cancer.
Johnson & Johnson unveiled a settlement offer of up to $5.5 billion to resolve roughly 69,000 talc-related lawsuits claiming its baby powder caused ovarian cancer. The plan would pay up to $3 billion next year, with no further payments due before 2028, and requires acceptance by legal firms representing about 95% of the claims. J&J denies that talc caused cancer, notes it has stopped selling talc-based powder worldwide and shifted to a cornstarch-based product, and says the deal would allow it to focus on its core health-care mission while ending the litigation.
Healthcare stocks outperformed the broader market as Eli Lilly (LLY), Johnson & Johnson (JNJ) and AbbVie (ABBV) hit fresh 52-week highs (with Merck near highs), while biotech names like Moderna led rallies; the Health Care Select Sector SPDR ETF XLV has climbed about 3% year-to-date, signaling renewed investor interest in defensive healthcare plays amid ongoing M&A activity.
Turning $500,000 into a six-figure inflation‑adjusted dividend income isn’t about chasing the highest yield. It’s about blending modest, durable yields with steady dividend growth to compound over 20–30 years. The piece lays out three paths: a conservative 3.5% yield with 7% annual growth (e.g., Johnson & Johnson, Procter & Gamble) could reach about $130k by year 30; a 5% yield portfolio (Realty Income) offers earlier cash but slower compounding; and a high-yield, durability‑conscious 10% yield (AGNC) carries greater risk to principal. It emphasizes total returns, tax considerations, reinvesting dividends, and patience to grow income over time.
At the WSJ Leadership Institute summit, Johnson & Johnson CEO Joaquin Duato said the company aims to eliminate cancer within 10 years, citing breakthroughs in immunotherapy that have extended remission in multiple myeloma and improved longevity, with AI and biomarkers enabling earlier diagnosis and more personalized treatments. He suggested some cancers could be cured while others become chronic, and noted J&J's acquisitions like Firefly Bio to target difficult mutations, alongside advances such as a melanoma vaccine study by Merck and Moderna that underscores rapid progress in oncology.
Johnson & Johnson announced a more than $1 billion investment in Jacksonville, Florida to scale U.S.-based Vision manufacturing, packaging, and a new distribution facility as part of a $55 billion U.S. investment through 2029. The upgrades aim to boost ACUVUE contact lens production for about 40 million patients, support 3,500 local jobs, and strengthen supply chain resilience, with the facility slated to be fully operational in 2028 and Florida’s economy benefiting from an estimated $6 billion annual impact.
Johnson & Johnson is paying $1 billion upfront to acquire Firefly Bio and its Firelink degrader antibody conjugate (DAC) platform, gaining a technology that links catalytic protein degraders to antibodies to target KRAS-driven tumors and expand its innovative medicine pipeline. Firefly has shown preclinical tumor reductions at very low doses, and the deal underscores rising pharma interest in DACs, which are drawing attention after multiple partnerships and acquisitions in the space.
In a multi-country trial, Johnson & Johnson’s amivantamab shrank or eradicated tumors in patients with head and neck cancer (and some lung cancers) that had stopped responding to chemotherapy or immunotherapy; 43 of 102 patients responded (28 partial shrinkages, 15 complete disappearances), with results to be presented at ASCO in Chicago; the drug works by targeting tumor growth proteins and activating the immune system, and median survival was about 12.5 months, with ongoing trials to explore broader use.
The Lancet has retracted a 1977 unsigned commentary on cosmetic talc after discovering the author was a paid Johnson & Johnson consultant, revealing an undeclared conflict of interest; editors say such unsigned pieces would not be published today, and the decision comes amid decades of talc-related litigation and ongoing debates over asbestos testing in cosmetics, including a FDA rule proposal later withdrawn in 2025.
Johnson & Johnson won U.S. approval for Icotyde, a daily oral medication for moderate-to-severe plaque psoriasis in patients 12 and older, designed to mimic the effects of top-selling injectables like Skyrizi and Tremfya without injections. The pill could expand the patient market and is projected to reach more than $5 billion in peak annual sales, potentially reshaping competition in a multibillion-dollar field.
Johnson & Johnson announced more than a $1 billion investment to build a next-generation cell-therapy manufacturing facility in Lower Gwynedd, Montgomery County, Pennsylvania, expanding U.S. manufacturing capacity, creating 500+ biomanufacturing jobs and up to 4,000 construction roles, as part of a broader $55 billion U.S. investment through 2029 to advance cancer, immune-mediated, and neurological therapies.
Johnson & Johnson announced a more-than-$1 billion plan to build a next-generation cell-therapy manufacturing facility on a 154-acre site in Spring House, Lower Gwynedd, to expand U.S. manufacturing for cancer, immune-mediated and neurological diseases. The project is expected to create about 4,000 construction jobs and 500 skilled biomanufacturing roles; J&J already operates a large facility in the area with about 2,500 workers. Pennsylvania officials welcomed the investment as a boost to the state's life sciences and workforce.
Johnson & Johnson is expanding its operations in Wilson, North Carolina, with a multibillion-dollar investment to build a new factory that will produce cancer drugs, creating hundreds of new jobs. The state is supporting this growth with a $12 million program to train workers, highlighting North Carolina's appeal for life sciences companies and its focus on workforce development.
Johnson & Johnson has reached an agreement with the US government to lower drug prices for Americans in exchange for tariff exemptions, participating in initiatives to make medicines more affordable and building new manufacturing facilities in the US as part of a broader investment plan.
Johnson & Johnson has reached an agreement with the U.S. government to lower drug prices for Americans in exchange for tariff exemptions, participating in discounted drug sales and expanding manufacturing investments in the U.S.